Brian Skorney
Stock Analyst at Baird
(3.47)
# 936
Out of 5,008 analysts
116
Total ratings
44.58%
Success rate
7.16%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $42.50 | +45.88% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $15.02 | +246.21% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $23.12 | +51.38% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $62.11 | +94.82% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $13.95 | +129.39% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $152.21 | +67.53% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $583.24 | +0.64% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $73.74 | -25.41% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $116.78 | -14.37% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.78 | +117.71% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $1.07 | +367.29% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $11.08 | +80.51% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.51 | +454.32% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $5.94 | +68.35% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $295.54 | -27.25% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $137.00 | +31.39% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $8.34 | +235.73% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $10.51 | +271.08% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $39.16 | +60.88% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $410.28 | -20.79% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $16.11 | -37.93% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $3.96 | +6,718.18% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.73 | +26.85% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.62 | +18,418.52% | 3 | May 7, 2018 |
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $42.50
Upside: +45.88%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $15.02
Upside: +246.21%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $23.12
Upside: +51.38%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $62.11
Upside: +94.82%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $13.95
Upside: +129.39%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $152.21
Upside: +67.53%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $583.24
Upside: +0.64%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $73.74
Upside: -25.41%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $116.78
Upside: -14.37%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.78
Upside: +117.71%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $1.07
Upside: +367.29%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $11.08
Upside: +80.51%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.51
Upside: +454.32%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $5.94
Upside: +68.35%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $295.54
Upside: -27.25%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $137.00
Upside: +31.39%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $8.34
Upside: +235.73%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $10.51
Upside: +271.08%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $39.16
Upside: +60.88%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $410.28
Upside: -20.79%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $16.11
Upside: -37.93%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $3.96
Upside: +6,718.18%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.73
Upside: +26.85%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.62
Upside: +18,418.52%